Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Nephros (NEPH) EBITDA Margin (2016 - 2025)

Nephros (NEPH) has 16 years of EBITDA Margin data on record, last reported at 6.59% in Q3 2025.

  • For Q3 2025, EBITDA Margin rose 74.0% year-over-year to 6.59%; the TTM value through Sep 2025 reached 8.06%, up 1495.0%, while the annual FY2024 figure was 0.04%, 1110.0% up from the prior year.
  • EBITDA Margin reached 6.59% in Q3 2025 per NEPH's latest filing, up from 5.61% in the prior quarter.
  • Across five years, EBITDA Margin topped out at 11.61% in Q1 2025 and bottomed at 139.48% in Q3 2022.
  • Average EBITDA Margin over 5 years is 25.55%, with a median of 12.21% recorded in 2023.
  • Peak YoY movement for EBITDA Margin: plummeted -9425bps in 2022, then soared 13461bps in 2023.
  • A 5-year view of EBITDA Margin shows it stood at 49.81% in 2021, then skyrocketed by 49bps to 25.53% in 2022, then grew by 21bps to 20.1% in 2023, then surged by 141bps to 8.19% in 2024, then decreased by -20bps to 6.59% in 2025.
  • Per Business Quant database, its latest 3 readings for EBITDA Margin were 6.59% in Q3 2025, 5.61% in Q2 2025, and 11.61% in Q1 2025.